Yes, obstructive sleep apnea (OSA) can cause pulmonary hypertension (PH). The repeated drops in oxygen that happen during apnea episodes trigger a chain of responses in the lungs’ blood vessels that, over time, raises pressure in the pulmonary arteries. Roughly 9% of people with OSA alone develop pulmonary hypertension, and that number climbs sharply with more severe sleep apnea and the presence of other lung conditions.
How OSA Raises Pressure in the Lungs
During an apnea episode, your upper airway collapses for ten seconds or more, cutting off airflow. This does two things simultaneously: it starves your blood of oxygen and creates extreme suction pressure inside your chest, sometimes pulling as low as negative 60 mmHg. Both of these forces stress the blood vessels in your lungs.
When oxygen levels drop, your lung vessels reflexively constrict to redirect blood toward areas of the lung that are getting more air. This response, called hypoxic pulmonary vasoconstriction, is a short-term safety mechanism. But in someone with OSA, it fires repeatedly throughout the night, every night. Over months and years, the vessel walls start to physically change. Smooth muscle cells and connective tissue cells multiply inside the artery walls, thickening them and narrowing the space blood flows through. This structural remodeling is what makes the pressure elevation permanent rather than something that resolves when you wake up.
On top of the oxygen-driven damage, each blocked breath also destabilizes the autonomic nervous system, the part of your nervous system that controls heart rate and blood vessel tone. The resulting surges in sympathetic (“fight or flight”) activity cause swings in heart rate and cardiac output that add further strain to the right side of the heart, which is responsible for pumping blood through the lungs.
How Common This Is
Not everyone with OSA develops pulmonary hypertension, but the risk tracks closely with how severe the apnea is. In one study of patients with confirmed OSA, researchers measured pulmonary artery pressures using echocardiography and found a clear dose-dependent pattern. Among those with severe OSA (30 or more breathing interruptions per hour), 65 out of the total group had elevated pressures, including 8 with moderate PH and 4 with severe PH. Patients with mild OSA (5 to 14 events per hour) had only mild elevations when PH was present at all. The statistical correlation between apnea severity and pulmonary artery pressure was strong (r = 0.695), meaning that as one goes up, the other reliably does too.
To put this in perspective, pulmonary hypertension is now defined as a mean pulmonary artery pressure above 20 mmHg, measured by catheterization. That threshold was lowered from the older cutoff of 25 mmHg after large studies showed that mortality and hospitalization risk begin climbing once pressure exceeds 20 mmHg.
COPD Makes It Significantly Worse
When someone has both OSA and chronic obstructive pulmonary disease, a combination known as overlap syndrome, the risk of pulmonary hypertension roughly quadruples. In a study comparing the two groups directly, 36% of overlap patients had pulmonary hypertension versus just 9% of those with OSA alone. The average pulmonary artery pressure in the overlap group was 20 mmHg compared to 15 mmHg in the OSA-only group, a difference that was highly statistically significant.
This makes sense physiologically: COPD damages the lungs in ways that lower baseline oxygen levels even during the day, so the nighttime drops from apnea episodes are hitting an already-compromised system. If you have both conditions, screening for pulmonary hypertension becomes especially important.
What It Means for Your Health
Pulmonary hypertension adds a measurable layer of risk. Among hospitalized OSA patients, those who also had pulmonary hypertension had an in-hospital mortality rate of 3.1%, compared to 1.6% for OSA patients without it. While those numbers reflect a hospitalized population rather than all OSA patients, they illustrate how PH compounds the cardiovascular burden that OSA already creates.
The strain primarily falls on the right ventricle of your heart. This chamber has to push blood through increasingly stiff, narrow pulmonary arteries. Over time, it can enlarge and weaken. Blood tests that measure cardiac stress markers like NT-proBNP tend to be higher in people with this combination, reflecting increased wall stress in both the right and left sides of the heart along with enlargement of the heart’s upper chambers.
How It’s Detected
Echocardiography is the standard first step for screening. It uses ultrasound to estimate the pressure in your pulmonary arteries by measuring how fast blood flows backward through a valve in the right side of your heart. Studies show echocardiography correlates well with the gold-standard test (right heart catheterization) and has a sensitivity around 89% when using a cutoff of 40 mmHg for systolic pulmonary artery pressure. That means it catches the vast majority of cases.
Where echocardiography falls short is specificity. It can overestimate or underestimate pressures in individual patients, with one study finding its accuracy at only 43% when compared case by case against catheterization. So if your echocardiogram suggests pulmonary hypertension, your doctor may confirm it with catheterization, which involves threading a thin pressure sensor into the pulmonary artery through a vein. This gives a precise reading and helps determine exactly what type of PH you have.
CPAP Treatment Can Reverse the Damage
The most encouraging finding in this area is that treating OSA with continuous positive airway pressure (CPAP) can substantially lower pulmonary artery pressures. A meta-analysis pooling data from multiple studies found that CPAP therapy was associated with an average reduction of 13.3 mmHg in pulmonary artery pressure. Treatment durations across the included studies ranged from 3 to 70 months.
A 13 mmHg drop is clinically meaningful. For someone with mild to moderate pulmonary hypertension, that reduction could bring pressures back to normal or near-normal range. The key requirement is consistent use. CPAP works by keeping the airway open during sleep, preventing the oxygen drops and pressure swings that drive the vascular damage in the first place. When those nightly insults stop, the blood vessels can begin to relax and, to some extent, reverse the remodeling process.
For people whose pulmonary hypertension doesn’t fully resolve with CPAP, particularly those with severe PH or overlap syndrome, additional treatments targeting the pulmonary vasculature may be considered. But CPAP remains the foundation because it addresses the root cause rather than just managing the downstream effects.